Efficacy and Safety of Pemafibrate Extended-Release Tablet: a Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Comparison Trial-Reference-Cited by-同舟云学术

Efficacy and Safety of Pemafibrate Extended-Release Tablet: a Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Comparison Trial

Published:2024 Issue: Volume: Page:
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Arai Hidenori¹,Yamashita Shizuya²,Araki Eiichi³⁴,Yokote Koutaro⁵,Tanigawa Ryohei⁶,Saito Ayumi⁶,Yamasaki Sayumi⁷,Suganami Hideki⁸,Ishibashi Shun⁹

Affiliation:

1. National Center for Geriatrics and Gerontology

2. Rinku General Medical Center

3. Kikuchi Medical Association Hospital

4. Research Center for Health and Sports Sciences, Kumamoto Health Science University

5. Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine

6. Global Clinical Development Department, Kowa Company, Ltd.

7. Medical Affairs Department, Kowa Company, Ltd.

8. Data Science Center, Kowa Company, Ltd.

9. Division of Endocrinology and Metabolism, Department of Internal Medicine, School of Medicine, Jichi Medical University

Publisher

Japan Atherosclerosis Society

Link

https://www.jstage.jst.go.jp/article/jat/advpub/0/advpub_64677/_pdf

Reference21 articles.

1. 1) Fruchart JC: Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists. Cardiovasc Diabetol, 2013; 12: 82

2. 2) Sahebkar A, Chew GT, Watts GF: New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin Pharmacother, 2014; 15: 493-503

3. 3) Pawlak M, Lefebvre P, Staels B: Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol, 2015; 62: 720-733

4. 4) Claxton AJ, Cramer J, Pierce C: A systematic review of the associations between dose regimens and medication compliance. Clin Ther, 2001; 23: 1296-1310

5. 5) Ishibashi S, Arai H, Yokote K, Araki E, Suganami H, Yamashita S; K-877 Study Group: Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol, 2018; 12: 173-184

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Once-daily Extended-Release Pemafibrate Enhances Adherence and Triglyceride Control Over Twice-Daily Dosing;Journal of Atherosclerosis and Thrombosis;2024